The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918
Abstract
PURPOSE: We discovered that breast cancer resistance protein (BCRP), a recently identified adenosine triphosphate–binding cassette drug transporter, substantially limits the oral bioavailability of topotecan in mdr1a/1b(−/−) P-glycoprotein (P-gp) knockout and wild-type mice. GF120918 is a potent inhibitor of BCRP and P-gp. The aim was to increase the bioavailability of topotecan by GF120918. PATIENTS AND METHODS: In cohort A, eight patients received 1.0 mg/m 2 oral topotecan with or without coadministration of one single oral dose of 1,000 mg GF120918 (day 1 or day 8). In cohort B, eight other patients received 1.0 mg/m 2 intravenous topotecan with or without 1,000 mg oral GF120918 to study the effect of GF120918 on the systemic clearance of topotecan. RESULTS: After oral topotecan, the mean area under the plasma concentration-time curve (AUC) of total topotecan increased significantly from 32.4 ± 9.6 μg·h/L without GF120918 to 78.7 ± 20.6 μg·h/L when GF120918 was coadministered (P = .008). The mean maximum plasma concentration of total topotecan increased from 4.1 ± 1.5 μg/L without GF120918 to 11.5 ± 2.4 μg/L with GF120918 (P = .008). The apparent bioavailability in this cohort increased significantly from 40.0% (range, 32% to 47%) to 97.1% (range, 91% to 120%) (P = .008). Interpatient variability of the apparent bioavailability was 17% without and 11% with GF120918. After intravenous administration of topotecan, coadministration of oral GF120918 had a small but statistically significant effect on the AUC and systemic clearance of total topotecan but no statistically significant effect on maximum plasma concentration and terminal half-life of total topotecan. CONCLUSION: Coadministration of the BCRP and P-gp inhibitor GF120918 resulted in a significant increase of the systemic exposure of oral topotecan. The apparent oral bioavailability increased from 40.0% without to 97.1% with GF120918.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C. L. M., Schinkel, A. H., van de Vijver, M. J., Scheper, R. J., & Schellens, J. H. M. (2001) · PubMed · Cited by 1,130
Self-citationvon Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., Stewart, D. J., Clark, P. I., Palmer, M. C., Depierre, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.658 · Cited by 968
Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan
Jonker, J. W. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.20.1651 · Cited by 638
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Maliepaard, M., van Gastelen, M. A., de Jong, L. A., Pluim, D., van Waardenburg, R. C., Ruevekamp, M. C., Floot, B. G., & Schellens, J. H. M. (1999) · PubMed · Cited by 487
Self-citationA kinetic and Mechanistic Study of the Hydrolysis of Camptothecin and Some Analogues
Fassberg, J., & Stella, V. J. (1992) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600810718 · Cited by 464
Allen, J. D., Brinkhuis, R. F., Wijnholds, J., & Schinkel, A. H. (1999) · PubMed · Cited by 353
DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues.
Hsiang, Y. H., Liu, L. F., Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Kirschenbaum, S., Silber, R., & Potmĕsil, M. (1989) · PubMed · Cited by 339
Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR
de Bruin, M., Miyake, K., Litman, T., Robey, R., & Bates, S. E. (1999) · Cancer Letters · doi:10.1016/s0304-3835(99)00182-2 · Cited by 298
Maliepaard, M., van Gastelen, M. A., Tohgo, A., Hausheer, F. H., van Waardenburg, R. C. A. M., de Jong, L. A., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2001) · PubMed · Cited by 231
Self-citationHendricks, C. B., Rowinsky, E. K., Grochow, L. B., Donehower, R. C., & Kaufmann, S. H. (1992) · PubMed · Cited by 210
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Terwogt, J. M. M., Malingré, M. M., Beijnen, J. H., Huinink, W. W. T. B., Rosing, H., Koopman, F. J., van Tellingen, O., Swart, M., & Schellens, J. H. M. (1999) · PubMed · Cited by 205
Self-citationCoadministration of Cyclosporine Strongly Enhances the Oral Bioavailability of Docetaxel
Malingré, M. M., Richel, D. J., Beijnen, J. H., Rosing, H., Koopman, F. J., Ten Bokkel Huinink, W. W., Schot, M. E., & Schellens, J. H. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1160 · Cited by 199
Self-citationClinical Pharmacokinetics of Topotecan
Herben, V. M. M., ten Bokkel Huinink, W. W., & Beijnen, J. H. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631020-00001 · Cited by 180
Self-citationHochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Raphael, B., & Vinci, R. Z. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.3.553 · Cited by 162
Malingré, M. M., Beijnen, J. H., Rosing, H., Koopman, F. J., Jewell, R. C., Paul, E. M., Huinink, W. W. T. B., & Schellens, J. H. M. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1543 · Cited by 154
Self-citationvan Asperen, J., van Tellingen, O., van der Valk, M. A., Rozenhart, M., & Beijnen, J. H. (1998) · PubMed · Cited by 138
Self-citationSaltz, L. B., Sirott, M. N., Young, C. W., Tong, W. P., Niedzwiecki, D., Tzy-Jyun, Y., Tao, Y., Trochanowski, B. J., Wright, P., Barbosa, K., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.18.1499 · Cited by 133
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor
Schellens, J. H. M., Creemers, G. J. M., Beijnen, J. H., Rosing, H., de Boer-Dennert, M. M., McDonald, M., Davies, B., & Verweij, J. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.243 · Cited by 131
Self-citationTHE PHARMACOLOGICAL ROLE OF P-GLYCOPROTEIN IN THE INTESTINAL EPITHELIUM
van Asperen, J., van Tellingen, O., & Beijnen, J. H. (1998) · Pharmacological Research · doi:10.1006/phrs.1998.0326 · Cited by 130
Self-citationSparreboom, A., Planting, A. S. T., Jewell, R. C., van der Burg, M. E., van der Gaast, A., de Bruijn, P., Loos, W. J., Nooter, K., Chandler, L. H., Paul, E. M., et al. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199909000-00005 · Cited by 94
Self-citationWitherspoon, S. M., Emerson, D. L., Kerr, B. M., Lloyd, T., Dalton, W. S., & Wissel, P. S. (1996) · PubMed · Cited by 67
Gerrits, C. J., Burris, H. A., Schellens, J. H. M., Planting, A. S. T., van den Burg, M. E. L., Rodriguez, G. I., van Beurden, V., Loos, W. J., Hudson, I., Fields, S. Z., et al. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10173-3 · Cited by 65
Self-citationGerrits, C. J., Burris, H. A., Schellens, J. H. M., Eckardt, J. R., Planting, A. S. T., van der Burg, M. E., Rodriguez, G. I., Loos, W. J., van Beurden, V., Hudson, I., et al. (1998) · PubMed · Cited by 37
Self-citation
Cited by
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00169-2 · Cited by 1,386
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.027 · Cited by 1,231
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
Austin Doyle, L., & Ross, D. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206938 · Cited by 1,051
Jonker, J. W., Buitelaar, M., Wagenaar, E., van der Valk, M. A., Scheffer, G. L., Scheper, R. J., Plösch, T., Kuipers, F., Elferink, R. P. J. O., Rosing, H., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202607599 · Cited by 822
Self-citation
Metadata
- Authors
- Kruijtzer, C. M. F., Beijnen, J. H., Rosing, H., ten Bokkel Huinink, W. W., Schot, M., Jewell, R. C., Paul, E. M., & Schellens, J. H. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-07-01
- Volume
- 20
- Issue
- 13
- Pages
- 2943-2950
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2166082449
- Cited by
- 464
- References
- 24
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.